These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 31360903)

  • 21. Frequency of pathogenic germline mutation in CHEK2, PALB2, MRE11, and RAD50 in patients at high risk for hereditary breast cancer.
    Kim H; Cho DY; Choi DH; Oh M; Shin I; Park W; Huh SJ; Nam SJ; Lee JE; Kim SW
    Breast Cancer Res Treat; 2017 Jan; 161(1):95-102. PubMed ID: 27783279
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Association of Germline CHEK2 Gene Variants with Risk and Prognosis of Non-Hodgkin Lymphoma.
    Havranek O; Kleiblova P; Hojny J; Lhota F; Soucek P; Trneny M; Kleibl Z
    PLoS One; 2015; 10(10):e0140819. PubMed ID: 26506619
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pathogenic and likely pathogenic variants in PALB2, CHEK2, and other known breast cancer susceptibility genes among 1054 BRCA-negative Hispanics with breast cancer.
    Weitzel JN; Neuhausen SL; Adamson A; Tao S; Ricker C; Maoz A; Rosenblatt M; Nehoray B; Sand S; Steele L; Unzeitig G; Feldman N; Blanco AM; Hu D; Huntsman S; Castillo D; Haiman C; Slavin T; Ziv E
    Cancer; 2019 Aug; 125(16):2829-2836. PubMed ID: 31206626
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Genetic and epigenetic analysis of CHEK2 in sporadic breast, colon, and ovarian cancers.
    Williams LH; Choong D; Johnson SA; Campbell IG
    Clin Cancer Res; 2006 Dec; 12(23):6967-72. PubMed ID: 17145815
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CHEK2 gene alterations independently increase the risk of death from breast cancer in Bulgarian patients.
    Angelova SG; Krasteva ME; Gospodinova ZI; Georgieva EI
    Neoplasma; 2012; 59(6):622-30. PubMed ID: 22862163
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The First Case Report of a Patient With Oligodendroglioma Harboring
    Li X; Xue H; Luo N; Han T; Li M; Jia D
    Front Genet; 2022; 13():718689. PubMed ID: 35281821
    [No Abstract]   [Full Text] [Related]  

  • 27. Germline variant profiling of CHEK2 sequencing variants in breast cancer patients.
    McCarthy-Leo C; Baughan S; Dlugas H; Abraham P; Gibbons J; Baldwin C; Chung S; Feldman GL; Dyson G; Finley RL; Tainsky MA
    Cancer Genet; 2024 Nov; 288-289():10-19. PubMed ID: 39208550
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Morphology and genomic hallmarks of breast tumours developed by ATM deleterious variant carriers.
    Renault AL; Mebirouk N; Fuhrmann L; Bataillon G; Cavaciuti E; Le Gal D; Girard E; Popova T; La Rosa P; Beauvallet J; Eon-Marchais S; Dondon MG; d'Enghien CD; Laugé A; Chemlali W; Raynal V; Labbé M; Bièche I; Baulande S; Bay JO; Berthet P; Caron O; Buecher B; Faivre L; Fresnay M; Gauthier-Villars M; Gesta P; Janin N; Lejeune S; Maugard C; Moutton S; Venat-Bouvet L; Zattara H; Fricker JP; Gladieff L; Coupier I; ; ; ; Chenevix-Trench G; Hall J; Vincent-Salomon A; Stoppa-Lyonnet D; Andrieu N; Lesueur F
    Breast Cancer Res; 2018 Apr; 20(1):28. PubMed ID: 29665859
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bi-allelic alterations in DNA repair genes underpin homologous recombination DNA repair defects in breast cancer.
    Mutter RW; Riaz N; Ng CK; Delsite R; Piscuoglio S; Edelweiss M; Martelotto LG; Sakr RA; King TA; Giri DD; Drobnjak M; Brogi E; Bindra R; Bernheim G; Lim RS; Blecua P; Desrichard A; Higginson D; Towers R; Jiang R; Lee W; Weigelt B; Reis-Filho JS; Powell SN
    J Pathol; 2017 Jun; 242(2):165-177. PubMed ID: 28299801
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pathogenic Variants in Adult-Onset Cancer Predisposition Genes in Pediatric Cancer: Prevalence and Impact on Tumor Molecular Features and Clinical Management.
    McGee RB; Oak N; Harrison L; Xu K; Nuccio R; Blake AK; Mostafavi R; Lewis S; Taylor LM; Kubal M; Ouma A; Hines-Dowell SJ; Cheng C; Furtado LV; Nichols KE
    Clin Cancer Res; 2023 Apr; 29(7):1243-1251. PubMed ID: 36693186
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cyclin-Dependent Kinase 4/6 Inhibitor Outcomes in Patients With Advanced Breast Cancer Carrying Germline Pathogenic Variants in DNA Repair-Related Genes.
    Bruno L; Ostinelli A; Waisberg F; Enrico D; Ponce C; Rivero S; Blanco A; Zarba M; Loza M; Fabiano V; Amat M; Pombo MT; Noro L; Chacón M; Coló F; Chacón R; Nadal J; Nervo A; Costanzo V
    JCO Precis Oncol; 2022 Mar; 6():e2100140. PubMed ID: 35235412
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Atypical
    Borja NA; Silva-Smith R; Huang M; Parekh DJ; Sussman D; Tekin M
    Front Oncol; 2023; 13():1068110. PubMed ID: 36865800
    [TBL] [Abstract][Full Text] [Related]  

  • 33.
    Abdelghani E; Schieffer KM; Cottrell CE; Audino A; Zajo K; Shah N
    Cancers (Basel); 2023 Mar; 15(6):. PubMed ID: 36980535
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Alternative splicing and mutation status of CHEK2 in stage III breast cancer.
    Staalesen V; Falck J; Geisler S; Bartkova J; Børresen-Dale AL; Lukas J; Lillehaug JR; Bartek J; Lønning PE
    Oncogene; 2004 Nov; 23(52):8535-44. PubMed ID: 15361853
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer.
    Walsh T; Casadei S; Coats KH; Swisher E; Stray SM; Higgins J; Roach KC; Mandell J; Lee MK; Ciernikova S; Foretova L; Soucek P; King MC
    JAMA; 2006 Mar; 295(12):1379-88. PubMed ID: 16551709
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Li-Fraumeni syndrome: not a straightforward diagnosis anymore-the interpretation of pathogenic variants of low allele frequency and the differences between germline PVs, mosaicism, and clonal hematopoiesis.
    Batalini F; Peacock EG; Stobie L; Robertson A; Garber J; Weitzel JN; Tung NM
    Breast Cancer Res; 2019 Sep; 21(1):107. PubMed ID: 31533767
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Impact of germline BRCA2 and CHEK2 mutations on time to castration resistance in patients with metastatic hormone-nave prostate cancer].
    Matveev VB; Kirichek AA; Filippova MG; Savinkova AV; Khalmurzaev OA; Lyubchenko LN
    Urologiia; 2019 Dec; (5):79-85. PubMed ID: 31808637
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Recontacting non-BRCA1/2 breast cancer patients for germline CHEK2 c.1100del pathogenic variant testing: uptake and patient experiences.
    Velthuizen ME; van der Luijt RB; de Vries BJ; Koudijs MJ; Bleiker EMA; Ausems MGEM
    Hered Cancer Clin Pract; 2021 Jan; 19(1):9. PubMed ID: 33468213
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Increased Risk for Other Cancers in Addition to Breast Cancer for CHEK2*1100delC Heterozygotes Estimated From the Copenhagen General Population Study.
    Näslund-Koch C; Nordestgaard BG; Bojesen SE
    J Clin Oncol; 2016 Apr; 34(11):1208-16. PubMed ID: 26884562
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Germline mutations in the CHEK2 kinase gene are associated with an increased risk of bladder cancer.
    Złowocka E; Cybulski C; Górski B; Debniak T; Słojewski M; Wokołorczyk D; Serrano-Fernández P; Matyjasik J; van de Wetering T; Sikorski A; Scott RJ; Lubiński J
    Int J Cancer; 2008 Feb; 122(3):583-6. PubMed ID: 17918154
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.